What Does Intrathecal Mean in Medicine?

Intrathecal means “within the theca,” referring to the fluid-filled space surrounding your spinal cord and brain. In practical medical terms, an intrathecal procedure delivers medication, contrast dye, or other substances directly into the cerebrospinal fluid (CSF) by injection or implanted device. The reason this matters is that the brain and spinal cord sit behind a formidable biological filter called the blood-brain barrier, which blocks most drugs given by mouth or intravenously. Going intrathecal sidesteps that barrier entirely, which makes it the preferred route for treating a surprisingly wide range of conditions, from chronic pain and spasticity to leukemia and rare genetic diseases.

The Anatomy Behind the Term

Your spinal cord and brain are wrapped in three protective membranes called meninges. The outermost is the dura mater, a tough fibrous layer. Beneath it sits the arachnoid, a web-like membrane. The innermost layer, the pia mater, clings directly to the surface of the spinal cord. Between the arachnoid and the pia is a gap called the subarachnoid space, and this is the intrathecal space. It is filled with cerebrospinal fluid, along with spinal nerves and small blood vessels.¹ CSF cushions the brain and spinal cord, removes waste products, and circulates nutrients. When clinicians inject into this space, the drug mixes with that fluid and can reach the central nervous system without having to cross the blood-brain barrier.

The blood-brain barrier is made up of tightly packed cells lining the blood vessels in the brain. It does an excellent job keeping toxins and pathogens out, but it also blocks the vast majority of therapeutic molecules. That is a serious problem when disease strikes the brain or spinal cord. Intrathecal administration solves this by placing the drug exactly where it needs to be.² Because the drug goes straight into the CSF, effective doses are often dramatically smaller than what you would need intravenously, which in turn reduces side effects throughout the rest of the body.

How an Intrathecal Injection Is Performed

The most common method is a lumbar puncture, sometimes called a spinal tap. You sit hunched forward or lie on your side in a curled position so the spaces between your lower vertebrae open up. The clinician numbs a small area of skin in the lower back, then guides a thin needle between the vertebrae and through the dura into the CSF. The needle typically enters below the level where the spinal cord ends, so the cord itself is not at risk of being pierced. Once the needle is in place, medication can be injected, CSF can be withdrawn for testing, or both can happen during the same visit.

For patients who need repeated intrathecal treatments over weeks or months, a single needle stick each time is not always ideal. Two main alternatives exist. The first is an implantable pump, a small device placed under the skin of the abdomen that connects to a thin catheter threaded into the intrathecal space. The pump delivers a continuous or programmed dose of medication. It needs to be refilled periodically through the skin with a needle. The second option is an Ommaya reservoir, a dome-shaped device implanted under the scalp that connects to a catheter reaching into the brain’s ventricles, which are fluid-filled chambers continuous with the spinal CSF. Pressing a needle through the scalp into the reservoir allows clinicians to inject drugs or withdraw fluid.³ Ommaya reservoirs have also been used to deliver antibiotics directly into the ventricles for hard-to-treat brain infections caused by drug-resistant bacteria.⁴

Pain Management With Intrathecal Pumps

Chronic pain that no longer responds to oral medications is one of the most established reasons for intrathecal therapy. The two first-line intrathecal pain drugs are morphine and ziconotide. Morphine works in the intrathecal space much the way it does elsewhere, binding to opioid receptors, but because it is delivered so close to the spinal cord, far less is needed. Ziconotide takes a completely different approach: it blocks a specific type of calcium channel on nerve cells in the spinal cord, which stops pain-signaling chemicals from being released.⁵ The 2016 Polyanalgesic Consensus Conference guidelines recommended both as first-choice options for cancer and non-cancer chronic pain, though they emphasized ziconotide as the preferred starting point for non-cancer pain when it is not otherwise ruled out.⁶

Each drug has its own set of trade-offs. Intrathecal morphine can cause respiratory depression, and over time patients may need higher doses to get the same relief. It can also lead to a granuloma forming at the tip of the catheter, a small inflammatory mass that can press on the spinal cord and cause neurological symptoms. Ziconotide avoids the dependence issue and the granuloma risk, but it has a narrow dosing window: too much too fast can trigger psychiatric symptoms, and it is completely off limits for anyone with a history of psychosis.⁶ Catheter-tip granulomas, while rare, are serious enough that clinicians monitor for new or changing neurological symptoms in anyone receiving long-term intrathecal opioids.⁷

Managing Spasticity

Intrathecal baclofen is a well-known treatment for severe muscle spasticity, particularly in people with cerebral palsy, spinal cord injuries, or multiple sclerosis. Baclofen taken by mouth often causes drowsiness and other system-wide side effects at the doses needed to meaningfully relax spastic muscles. Delivering it straight into the CSF via an implanted pump lets clinicians use much less drug while still achieving a strong effect locally. A systematic review and meta-analysis of patients with cerebral palsy found that intrathecal baclofen reduced spasticity scores by roughly 40%, bringing the average score from about 3.2 down to 1.9 on standard clinical scales, with a weighted average dose of about 289 micrograms per day.⁸ Those numbers came from pooled data on over 300 patients, most of them teenagers, which gives them reasonable weight.

Intrathecal Chemotherapy for Blood Cancers

The central nervous system can act as a sanctuary for cancer cells, especially in blood cancers like acute lymphoblastic leukemia (ALL). Because systemic chemotherapy often cannot cross the blood-brain barrier in high enough concentrations, cancer cells hiding in the CSF can survive and later trigger a relapse. Without prophylactic intrathecal chemotherapy, more than half of ALL patients may develop central nervous system involvement.⁹ That statistic alone explains why intrathecal injections of chemotherapy drugs like methotrexate or cytarabine are a standard part of ALL treatment protocols.

The typical approach involves administering intrathecal chemotherapy at scheduled intervals during and after the main course of intravenous treatment. If a CNS relapse does occur, the treatment plan usually intensifies to include more frequent intrathecal therapy alongside systemic agents and, in some cases, radiation to the brain or spine.¹⁰ The evidence for prophylactic intrathecal chemotherapy is strongest in ALL. In acute myeloid leukemia (AML), the picture is less clear: one study comparing AML patients who did and did not receive prophylactic intrathecal chemo found CNS relapse rates were low in both groups, and the difference was not statistically significant.¹¹ This is an active area of debate, and the decision often comes down to individual risk factors.

Diagnosing Neurological Disease Through the Intrathecal Space

The intrathecal space is not just a delivery route; it is also a diagnostic window. Two broad categories of testing rely on accessing the CSF.

The first is myelography. A contrast dye is injected into the intrathecal space, and then imaging, usually CT, is performed. CT myelography provides detailed pictures of the spinal cord, nerve roots, and surrounding structures, and it remains an important tool for evaluating spinal cord compression, herniated discs, and other conditions where MRI may be unavailable, contraindicated, or inconclusive.¹² The technique has been around since the late 1970s, when clinicians first combined lumbar intrathecal contrast injection with computed tomography.¹³ Modern contrast agents are safer and better tolerated than the early formulations, but the basic principle is unchanged.

The second diagnostic use involves analyzing the CSF itself. A sample withdrawn during a lumbar puncture can be tested for infection, inflammation, abnormal cells, and specific protein markers. In multiple sclerosis (MS), one key test looks for oligoclonal bands, which are distinctive patterns of antibodies produced within the central nervous system. Finding these bands in the CSF but not in the blood is strong evidence of intrathecal immune activity and supports an MS diagnosis. In one large analysis, about 68% of suspected MS patients tested positive for oligoclonal bands.¹⁴ A newer biomarker called the kappa free light chain index may be even more sensitive. A study of 352 paired CSF and blood samples found that the kappa free light chain index caught some cases that oligoclonal band testing missed, and the difference was statistically significant, leading the researchers to suggest that using both tests together gives the best diagnostic picture.¹⁵

Risks and Complications

Any procedure that punctures the dura carries a risk of post-dural puncture headache (PDPH). This happens when CSF leaks out through the small hole left by the needle, lowering the fluid pressure around the brain. The headache is typically positional, feeling worse when you sit or stand up and better when you lie flat. It usually develops within five days and resolves on its own within two weeks, though an epidural blood patch, where a small amount of your own blood is injected into the epidural space to seal the leak, can speed recovery.¹⁶ Using thinner needles and certain needle-tip designs has reduced the incidence of PDPH significantly over the years.

A more serious but rarer concern with lumbar puncture is the risk of brain herniation in patients with significantly elevated intracranial pressure, such as those with large brain masses or acute bacterial meningitis with swelling. In that scenario, suddenly lowering pressure below the spine by draining CSF can cause brain tissue to shift downward. This is why clinicians often order imaging before performing a lumbar puncture in patients with signs of raised intracranial pressure.¹⁷

For patients with implanted intrathecal pumps, there is an additional rare hazard called a “pocket fill.” During a routine pump refill, if the needle misses the pump’s refill port and instead delivers medication into the tissue pocket around the device, the patient can absorb a large dose of drug systemically in an uncontrolled way. A 2011 review of Medtronic pump data reported 351 pocket-fill cases over roughly 14 years, eight of which were fatal. The estimated rate is about one in 10,000 refill procedures. A later analysis of over 77,000 refills found nine confirmed pocket-fill events.¹⁸ These numbers are small, but the consequences of a pocket fill can be severe, so refills are performed by trained personnel following strict protocols.

Getting Drug to the Brain Versus the Spinal Cord

An intrathecal injection in the lower back places drug right next to the lumbar spinal cord and nerve roots, which is ideal for pain or spasticity originating there. But what if the target is the brain? CSF does circulate upward, and the drug will eventually reach higher structures, but the fraction that makes it to the brain after a lumbar injection is modest. In a laboratory model simulating human CSF dynamics, less than about 12% of the injected dose reached the brain compartment within three hours of a lumbar injection, and tweaks like using a flush, adjusting catheter orientation, or increasing the injection volume produced only small improvements.¹⁹

This distribution challenge is one reason Ommaya reservoirs exist for brain-directed therapy, and it is why researchers are actively exploring new formulations, nanoparticle carriers, and injection strategies to improve how intrathecally delivered drugs spread through the central nervous system.² The limited brain penetration from a lumbar injection is also why conditions targeting the spinal cord or nearby structures tend to respond better to intrathecal therapy than conditions affecting the brain itself, at least with current techniques.

Gene Therapy and Newer Applications

Some of the most exciting developments in intrathecal medicine involve genetic and molecular therapies for diseases once considered untreatable. Nusinersen, approved in late 2016, was a landmark: it is an antisense oligonucleotide given by intrathecal injection to treat spinal muscular atrophy (SMA), a devastating genetic condition that destroys motor neurons. Because the drug cannot cross the blood-brain barrier from the bloodstream, intrathecal delivery is the only way to get it where it needs to go. Both children and adults with SMA receive repeated lumbar punctures for their nusinersen doses, which presents its own challenges, especially in patients with severe spinal deformities that can make needle placement difficult.²⁰

Beyond antisense drugs, researchers are using the intrathecal route to deliver gene therapy vectors, particularly adeno-associated viruses (AAV), directly into the CSF. The premise is straightforward: if you can get a viral vector carrying a corrective gene into the cerebrospinal fluid, it can reach cells across the brain and spinal cord. Animal studies have demonstrated that intrathecal AAV delivery achieves efficient gene transfer throughout the spinal cord and dorsal root ganglia.²¹ Large-animal studies have similarly shown that CSF-delivered AAV vectors can distribute gene therapy to cells throughout the brain and spinal cord, making a wide range of neurological diseases potential gene therapy targets.²² In a mouse model of a lysosomal storage disease (MPS VII), intrathecal AAV injection eliminated toxic storage granules in brain tissue, something intravenous delivery had failed to accomplish.²³

The intrathecal route is also being investigated for delivering antibodies, stem cells, and other biologic therapies for neurodegenerative diseases like Alzheimer’s and ALS.²⁴ Many of these are still in early clinical trials or preclinical stages, but the basic logic is the same one that has driven intrathecal medicine for over a century: the central nervous system is walled off from the rest of the body, so if you want to treat it, sometimes the only way in is through the cerebrospinal fluid.

A Procedure With a Long History

Intrathecal therapy is not a modern invention. The first documented use of intrathecal anesthesia dates to 1898, when the German surgeon August Bier injected cocaine into the spinal fluid to numb a patient for surgery. Just three years later, a Romanian surgeon presented results using intrathecal opioids at a conference in Paris. Those early experiments laid the groundwork for what is now routine spinal anesthesia in operating rooms worldwide, and over the following century the intrathecal route expanded from anesthesia into pain management, chemotherapy, diagnostics, and now gene therapy. The range of substances that clinicians put into the CSF has grown enormously, but the fundamental principle remains the same: when the blood-brain barrier stands in the way, go around it.